AP26113-13-201: A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib
This is a clinical trial of investigational drug AP26113 which will be administered orally.
IRB Protocol #
ARIAD Pharmaceuticals, Inc.
MICHAEL CROSS at (720)848-0592 or MICHAEL.CROSS@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. If you meet all the screening requirements for the study, you will have your next study visit within 2-3 weeks, where you will first receive the study drug. In general, you will be seen in the clinic three times the first month, and then every 4 weeks for the duration of your time on the study. An End of Treatment visit will occur within 21 days following your last dose of study drug or the date your physician feels it is in your best interest to stop taking the study drug. // Eligibility criteria include but are not limited to 18 years or older with lung cancer lung cancer resistant to a drug called crizotinib (brand name - Xalkori).Eligibility criteria include but are not limited to 18 years or older with lung cancer lung cancer resistant to a drug called crizotinib (brand name - Xalkori).